Relationship between Osteocalcin and Bone Alkaline Phosphatase in Patients with Diabetic Neuropathy.

Document Type : Original Article


1 Department of Chemistry/ College of Education for Pure Science Ibn Al-Haitham / University of Baghdad

2 Department of Biochemistry/ College of Medicine / University of Baghdad

3 Ministry of Education


The current study aimed to determine bone formation markers ( osteocalcin and bone alkaline phosphatase) as biomarkers for diagnosis the patients with diabetic neuropathy (DN) and to find the relationship between these markers and dyslipidemia in Iraqi patients with diabetic neuropathy, and if these patients are more prone to the risk of atherosclerosis disease.Subjects & Methods: in this study, serum samples were obtained from 25 healthy individuals as a control group (G1), 25 diabetic patients with dyslipidemia as a group (G2), and 25 diabetic patients without dyslipidemia as a group (G3). Age range (45-65) years for all subjects.Patients were attended in the National Diabetes Center / AL-Mustansiriya University/Baghdad. Serum was frozen until used for the analysis of FBG, Ocn , BALP, TG, Ch, HDL-ch, LDL-ch, and VLDL-ch. HbA1C is determined in whole blood.Results: the results showed a highly a significant increase in FBG,HbA1C, Ocn and BALP in G2 and G3 when compare with G1, and a significant difference in lipids levels between two patients groups and control. There is a significant negative correlation between serum Ocn and BALP. Serum Ocn and ALP level concentrations were independently and highly positively correlated with TG,VLDL-ch, and AIP ratio. Conclusions: Ocn and BALP were further increased in DN with complications and poor glycemic control. The AIP ratio was highly significant elevated in DN patients with and without dyslipidemia comparing with control ,therefore, these patients are more prone to the risk of atherosclerosis disease. Much remains to be further investigated to confirm such a relationship between Ocn and BALP, in addition, to clarify their role in DN. Changes in bone biomarkers can reflect these underlying changes ahead of time, enabling clinicians to respond fast and effectively, which allows bone biomarkers to be used as markers for DN diagnosis.


Main Subjects